← All diseases
Cancer
Lung cancer (small cell)
Do you want to receive a message when there is new research about Small Cell Lung Cancer (SCLC)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above every publication you see one sentence explaining what was studied — and you'll be notified as soon as there is new research about Small cell lung cancer. View what Premium costs.
Publications and studies (3263)
- Gut microbiota-associated nutritional-immune status predicts prognosis in postoperative NSCLC patients. (2026/12/31) ♡
- Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response. (2026/12/31) ♡
- Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM? (2026/12/01) ♡
- Letter regarding 'clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring SMARCA4 mutations'. (2026/12/01) ♡
- Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRAS(G12C) and modulating the KRAS/AKT/ERK signaling axis. (2026/09/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Innovative immune checkpoint modulators: monoclonal antibodies, small molecules, non-coding RNAs, and nanoparticles in cancer immunotherapy. (2026/09/01) ♡
- Systemic inflammatory response and complications developing in patients undergoing lobectomy for non-small-cell lung cancer: thoracotomy versus video-assisted thoracoscopic surgery. (2026/09/01) ♡
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. (2026/08/18) ♡
- KA-TMoE: A Deep Learning Method Using Time-Series CT Radiomics to Predict Post-Radiotherapy Rib Fractures in NSCLC Patients. (2026/08/10) ♡
- Novel Perfluoroalkyl Substance GenX exposure promotes non-small cell lung cancer progression by regulating the OTUB1/STAT3/VEGF axis. (2026/08/10) ♡
- Retraction notice to "YBX1 regulated by Runx3-miR-148a-3p axis facilitates non-small-cell lung cancer progression" [Cellular Signalling 85 (2021) 110049]. (2026/08/10) ♡
- Oncological Outcomes of Segmentectomy for Centrally Located Small-Sized Non-small-cell Lung Cancer: A Multicenter Study (CReGYT-02 Study). (2026/08/10) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Primed to React: Neutrophil-To-Lymphocyte Ratio to Predict Severe Checkpoint Inhibitor Pneumonitis. (2026/08/10) ♡
- Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety. (2026/08/10) ♡
- Construction of a survival prediction model and analysis of influencing factors for brain metastasis in non-small cell lung cancer based on multi‑parameter clinical data. (2026/08/10) ♡
- Is There Still Room for Monotherapy in EGFR-Mutated Non-Small Cell Lung Cancer? (2026/08/10) ♡
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. (2026/08/10) ♡
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations: Research Summary. (2026/08/10) ♡
- Liquid Biopsies for Cancer: A Translational Science Review. (2026/08/10) ♡
- Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. (2026/08/10) ♡
- MAGEA1 drives tumor progression via activation of the AKT pathway and correlates with elevated radiosensitivity in lung adenocarcinoma. (2026/08/10) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies. (2026/08/09) ♡
- Arsenic-responsive hsa_circ_0000118 couples early stress granule dynamics to later NF-κB-related signaling adaptation in NSCLC. (2026/08/08) ♡
- Siglec-15 and PD-1 checkpoint blockade in combination with oncolytic Zika virus infection confers protection against immune-resistant gliomas. (2026/08/08) ♡
- Myeloperoxidase/ASGPR Dual-Targeting Self-Amplifying Nanoplatform for Synergistic Anti-Metastatic Therapy of Hepatocellular Carcinoma. (2026/08/08) ♡
- Real-World Outcomes of Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Cohort Study From Vietnam. (2026/08/08) ♡
- Exploring multidimensional cfDNA methylation fragmentomics for non-invasive postoperative assessment in early-stage lung cancer. (2026/08/08) ♡
- Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched Analysis. (2026/08/08) ♡
- Salidroside Alleviates Mobocertinib-Induced Cardiotoxicity by Improving Cardiac Electrophysiology. (2026/08/08) ♡
- Clinical relative biological effectiveness of carbon-ion versus photon radiotherapy derived from tumor control probability models in locally advanced non-small cell lung cancer. (2026/08/08) ♡
- Deubiquitinase inhibition exposes a subtype-specific vulnerability in SCLC-P. (2026/08/07) ♡
- Lactate derived from CAFs mediates H3K18la in stemness gene promoters, which promotes tumor malignant phenotype formation. (2026/08/07) ♡
- Five-Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient-Initiated Nationwide Survey in Japan. (2026/08/07) ♡
- Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer. (2026/08/07) ♡
- Dosimetric impact of spatial separation in combined SBRT and mediastinal radiotherapy for peripheral small cell lung cancer. (2026/08/07) ♡
- A Transgenic mouse tolerant to syngeneic cancer cells expressing truncated human epidermal growth factor receptor. (2026/08/07) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Efficacy and safety of first-line immune checkpoint inhibitors combinations for extensive-stage small-cell lung cancer: A systematic review and network meta-analysis. (2026/08/07) ♡
- Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort. (2026/08/07) ♡
- EZH1/2 inhibition selectively targets SMARCA4/2 co-deficient lung cancer cells by suppressing stemness and proliferation. (2026/08/07) ♡
- Artificial intelligence-powered evaluation of the pathologic response to preoperative therapy in non-small cell lung cancer. (2026/08/07) ♡
- [Rescue Resections in Thoracic Surgery for Septic Lung Carcinomas Undergoing Systemic Therapy: a Case Series]. (2026/08/07) ♡
- Clonal LIMD1 loss drives PD-L1 immune evasion via ARIH1-dependent ubiquitination in lung cancer. (2026/08/07) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation. (2026/08/07) ♡
- Engineering Rigid Nanocarriers to Enhance Photothermal Performance for Suppressing Breast Cancer and Pulmonary Metastasis. (2026/08/07) ♡
- Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. (2026/08/07) ♡
- Immune signatures in NSCLC associated pleural effusions and implications for prognosis. (2026/08/07) ♡
- Efficacy and Safety of Sintilimab in Combination With Anlotinib and Chemoradiotherapy as First-Line Treatment for Driver Gene-Negative Oligometastatic Non-small Cell Lung Cancer: A Real-World Cohort Study. (2026/08/07) ♡
- Agent-Based Simulations of Lung Tumor Evolution Suggest That Ongoing Cell Competition Drives Realistic Clonal Expansions. (2026/08/06) ♡
- Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. (2026/08/06) ♡
- Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC. (2026/08/06) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.